Savara Pharma
Biotech · Public
Molgramostim, an inhaled recombinant GM-CSF (granulocyte-macrophage colony-stimulating factor) therapeutic for pulmonary alveolar proteinosis
savarapharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1223 | CHEMITOPE GLYCOPEPTIDE, LLC | — | $100K |
| 1224 | QENTOROS LLC | — | $605K |
| 1225 | Tetraphase Biosciences | — | — |
| 1226 | Savara Pharma | — | — |
| 1227 | NABGEN, INC. | — | $100K |
| 1228 | ERAD Therapeutics Inc. | — | $84K |
| 1229 | Gaingels LabGenius LLC | — | $64K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.